Abstract
Purpose
There are many medical treatments for enuresis. However, it is not known the effect of enuresis management according to when medication was started in the clinical field. Therefore, this study was conducted to determine the results of treating enuresis according to different starting points of the medication.
Materials and Methods
During March 2001 to May 2004, 331 patients among the 412 primary monosymptomatic enuresis patients were studied for over 6 months: they were treated to a combination of medical treatments and then the reduction of medication dose was taped. Patients less than 5 years old were in group A, the 6-7 years old were in group B, and the patients older than 8 years old were in group C. Successful medication was defined as 14 days of no enuresis without relapse, and failure was defined as 2 or more incidence of enuresis in 2 weeks or loss to follow up after 6 months of treatment.
Results
Group A included a total of 105 patients; 81 (77.1%) patients experienced successful treatment. Group B included a total of 111 patients, and 86 (77.5%) patients had a successful treatment. Group C included a total of 115 patients, and 79 (68.7%) patients had successful treatment. The mean medication period was 6.5±5.2 months for group A, 8.5±6.8 months for group B and 10.3±9.5 months for group C: these results showed statistical significance (p<0.05).
Figures and Tables
References
1. Butler RJ. Establishment of working definitions in nocturnal enuresis. Arch Dis Child. 1991. 66:267–271.
2. Forsythe WI, Redmond A. Enuresis and spontaneous cure rate. Study of 1,129 enuretis. Arch Dis Child. 1974. 49:259–263.
3. Lackgren G, Hjalmas K, van Gool J, von Gontard A, de Gennaro M, Lottmann H, et al. Nocturnal enuresis: a suggestion for a European treatment strategy. Acta Paediatr. 1999. 88:679–690.
4. Kahan E, Morel D, Amir J, Zelcer C. A controlled trial of desmopressin and behavioral therapy for nocturnal enuresis. Medicine. 1998. 77:384–388.
5. Knudsen UB, Ritting S, Norgaard JP, Lundemose JB, Pedersen EB, Djurhuus JC. Long-term treatment of nocturnal enuresis with desmopressin. A follow-up study. Urol Res. 1991. 19:237–240.
6. Hvistendahl GM, Rawashdeh YF, Kamperis K, Hansen MN, Rittig S, Djurhuus JC. The relationship between desmopressin treatment and voiding pattern in children. BJU Int. 2002. 89:917–922.
7. Jick H, Slone D, Shapiro S, Heinonen OP, Lawson DH. Adverse reactions to the tricyclic-antidepressant drugs. Report from Boston Collaboative Drug Surveillance Program. Lancet. 1972. 1:529–531.
8. Kang JY, Ha IS, Chung HI, Kim KM. Therapeutic effects of imipramine and DDAVP in enuresis children: a randomized prospective study. Korean J Urol. 2003. 44:665–671.
9. Leebeek-Groenewegen A, Blom J, Sukhai R, Van Der Heijden B. Efficacy of desmopressin combined with alarm therapy for monosymptomatic nocturnal enuresis. J Urol. 2001. 166:2456–2458.
10. Park SC, Moon KH, Kim KS. The effect of long-term use and tapered dose reduction to the relapse rate of enuresis in children with primary nocturnal enuresis. Korean J Urol. 2005. 46:909–913.
11. Seo YJ, Lee SD, Lee KS. Combination therapy of imipramine and desmopressin in children with monosymptomatic nocturnal enuresis. Korean J Urol. 2001. 42:1322–1327.
12. Hinde M, Hjertonsson M, Broberg A. Low self esteem of children with enuresis. Mental and social health compared in different groups. Lakartidningen. 1995. 92:3225–3229.
13. Van Tijen NM, Messer AP, Namdar Z. Perceived stress of nonturnal enuresis in childhood. Br J Urol. 1998. 81:Suppl 3. 98–99.
14. Foxman B, Valdez RB, Brook RH. Childhood enuresis: prevalence, perceived impact and prescribed treatments. Pediatrics. 1986. 77:482–487.
15. Yang HS, Kim HG, Park WH. Enuresis of elementary school children in Seoul and Gyeonggi province: results according to the treatment experiences. Korean J Urol. 2003. 44:419–423.
16. Butler RJ. Childhood nocturnal enuresis: developing a conceptual framework. Clin Psychol Rev. 2004. 24:909–931.
17. Kass EJ, Diokno AC, Montealegre A. Enuresis: principles of management and result of treatment. J Urol. 1979. 121:794–796.
18. Diokno AC, Lapides J. Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol. 1972. 108:307–309.
19. Norgaard JP, Pedersen EB, Djurhuus JC. Diurnal anti-diuretic-hormone levels in enuretics. J Urol. 1985. 134:1029–1031.
20. Bower WF, Moore KH, Shepherd RB, Adams RD. The epidemiology of childhood enuresis in Australia. Br J Urol. 1996. 78:602–606.
21. Evans JH. Evidence based management of nocturnal enuresis. BMJ. 2001. 323:1167–1169.
22. Kwon CK, Yoon YR. Clinical experience of imipramine and oral desmopressin combined therapy in the nocturnal enuretic children. Korean J Urol. 2000. 41:867–871.
23. Riccabona M, Oswald J, Glauninger P. Long-term use and tapered dose reduction of intranasal desmopressin in the treatment of enuretic children. Br J Urol. 1998. 81:Suppl 3. 24–25.
24. Hjalmas K, Arnold T, Bower W, Caione P, Chiozza LM, von Gontard A, et al. Nocturnal enuresis: an international evidence based management strategy. J Urol. 2004. 171:2545–2561.